← Back to Clinical Trials
Recruiting NCT04406662

NCT04406662 Routine Evaluation of People Living With Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04406662
Status Recruiting
Phase
Sponsor University of Edinburgh
Condition Cachexia; Cancer
Study Type OBSERVATIONAL
Enrollment 600 participants
Start Date 2020-07-15
Primary Completion 2029-08-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 600 participants in total. It began in 2020-07-15 with a primary completion date of 2029-08-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

People with incurable cancer often have complex individual needs, however there are several common themes encountered when considering this group. As cancer progresses there are series of interactions between the tumour and the patient, producing both local and systemic effects. This altered state of illness can have multiple ill effects including weight loss, fatigue, increased symptom burden and reduction in physical function which all contribute to a reduced quality of life. These areas are often studied in isolation, giving an incomplete picture. A detailed, holistic characterisation of this group of people does not exist. A robust characterisation of people with incurable cancer will allow identification and prioritisation of future research and has the potential to inform new therapeutics and provide justification for treatments. This study aims to collect information about symptoms and quality of life, weight loss and body composition, physical activity and the body's immune response to cancer. Participants with incurable cancer will be recruited to the study from oncology and palliative medicine services in the UK. Participants will answer questionnaires about quality of life and symptoms, have bloods taken for inflammatory marker and cytokine analysis and have their body composition measured by a variety of methods.

Eligibility Criteria

Inclusion Criteria: * Patients with incurable cancer (metastatic cancer (Clinical, histological, cytological or radiological evidence) or receiving anti-cancer therapy with palliative intent). * Aged 18-years and over * Written informed consent Exclusion Criteria: * Any concomitant medical or psychiatric problems which, in the opinion of the investigator, would increase the risk of complication for the participant and/or investigator. * Participants will not be able to take part in bio-impedance analysis if they have a pacemaker or implantable cardiac defibrillator.

Contact & Investigator

Central Contact

Barry JA Laird, MBCHB MD

✉ barry.laird@ed.ac.uk

📞 01316518611

Principal Investigator

Barry JA Laird, MBCHB MD

PRINCIPAL INVESTIGATOR

St Columba's Hospice/ University of Edinburgh

Frequently Asked Questions

Who can join the NCT04406662 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Cachexia; Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04406662 currently recruiting?

Yes, NCT04406662 is actively recruiting participants. Contact the research team at barry.laird@ed.ac.uk for enrollment information.

Where is the NCT04406662 trial being conducted?

This trial is being conducted at Edinburgh, United Kingdom.

Who is sponsoring the NCT04406662 clinical trial?

NCT04406662 is sponsored by University of Edinburgh. The principal investigator is Barry JA Laird, MBCHB MD at St Columba's Hospice/ University of Edinburgh. The trial plans to enroll 600 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology